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Abstract: A bone marrow-derived mesenchymal stromal cell (MSC) transplant and a bioengineered
nanofiber-hydrogel composite (NHC) have been shown to stimulate nervous tissue repair in the
contused spinal cord in rodent models. Here, these two modalities were combined to assess their
repair effects in the contused spinal cord in adult rats. Cohorts of contused rats were treated with
MSC in NHC (MSC-NHC), MSC in phosphate-buffered saline (MSC-PBS), NHC, or PBS injected into
the contusion site at 3 days post-injury. One week after injury, there were significantly fewer CD68+
cells in the contusion with MSC-NHC and NHC, but not MSC-PBS. The reduction in CD86+ cells in
the injury site with MSC-NHC was mainly attributed to NHC. One and eight weeks after injury, we
found a greater CD206+/CD86+ cell ratio with MSC-NHC or NHC, but not MSC-PBS, indicating a
shift from a pro-inflammatory towards an anti-inflammatory milieu in the injury site. Eight weeks
after injury, the injury size was significantly reduced with MSC-NHC, NHC, and MSC-PBS. At
this time, astrocyte, and axon presence in the injury site was greater with MSC-NHC compared
with MSC-PBS. We did not find a significant effect of NHC on MSC transplant survival, and hind
limb function was similar across all groups. However, we did find fewer macrophages at 1 week
post-injury, more macrophages polarized towards a pro-regenerative phenotype at 1 and 8 weeks
after injury, and reduced injury volume, more astrocytes, and more axons at 8 weeks after injury
in rats with MSC-NHC and NHC alone compared with MSC-PBS; these findings were especially
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significant between rats with MSC-NHC and MSC-PBS. The data support further study in the use of
an NHC-MSC combination transplant in the contused spinal cord.
Keywords: nanofiber-hydrogel composite; spinal cord injury; inflammation; macrophages; secondary
injury; astrocytes; axon growth

1. Introduction
The prevalent mechanism of spinal cord injury (SCI) in humans is a contusion, which
typically leads to nervous tissue damage and sensory and motor function loss [1,2]. The
limited endogenous repair of central nervous tissue and typically poor recovery of function
after a spinal cord contusion in humans motivates the ongoing search for reparative
treatments [1,3,4].
Studies in animal models of contusive SCI have shown that a transplant of bone
marrow-derived mesenchymal stromal cells (MSC) in the injury site elicited nervous tissue
repair and, albeit not in all cases, function improvements [5–11]. MSC secrete paracrine
factors [12–14] that can direct immunomodulatory effects [15–18], promote neuroprotection [12,13], and increase axon growth [19,20]. Transplanting MSC is considered a promising
strategy to treat SCI, but the overall effects of an MSC transplant on nervous tissue repair
in the injured spinal cord remain limited [6,9,21].
We demonstrated that an in situ forming, injectable nanofiber-hydrogel composite
(NHC) elicited nervous tissue repair in an adult rat model of contusive SCI [22]. The NHC
consists of poly(ε-caprolactone) (PCL) nanofibers interfacially bound to a hydrogel network formed from thiolated hyaluronic acid (HA-SH) and poly(ethylene glycol) diacrylate
(PEGDA). The composite has a shear storage modulus similar to that of the nervous tissue
in the spinal cord [23,24] and provides a sufficiently high porosity to support host cell
infiltration and migration [22,25]. Importantly, we showed that NHC modulated the inflammatory response towards anti-inflammatory, pro-regenerative, macrophage phenotypes,
and facilitated tissue formation in the injury site [22].
In the present study, we combined two repair modalities by using the NHC as a
transplant matrix for MSC. We investigated the combination’s therapeutic potential in
the contused adult rat thoracic spinal cord. The repair was assessed by evaluating immunomodulation, neuroprotection, and hindlimb locomotor function.
2. Materials and Methods
2.1. Animals
Adult female Sprague Dawley rats (n = 68, 200–220 g, Charles Rivers Laboratory;
Wilmington, MA, USA) were used in this study. All animal procedures were performed
according to the guidelines of the National Institutes of Health and the United States
Department of Agriculture at the Miami Project to Cure Paralysis at the University of
Miami, Miami, FL, and approved by the local Institutional Animal Care and Use Committee.
The Assessment and Accreditation of Laboratory Animal Care accredited the animal facility
where the procedures were performed. Pairs of rats were housed under a 12-h light/dark
cycle with ad libitum access to food and water.
2.2. NHC Preparation
NHC was made following the protocol previously described [22]. Briefly, nanofibers
were electrospun from a PCL solution (16% w/w; Sigma-Aldrich, St. Louis, MO, USA) in
a mixture of dichloromethane (Sigma-Aldrich) and dimethylformamide (9/1, v/v; SigmaAldrich). Poly(9,9-dioctylfluorene-alt-benzothiadiazole) (F8BT; Sigma-Aldrich), a green
fluorescent dye, was added to the PCL solution to enable fiber identification after injection [22]. Carboxyl groups were introduced to the surface of the fibers in a plasma cleaner
(expanded plasma cleaner; PDC-001; Harrick Plasma; Ithaca, NY, USA). These carboxyl
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groups were initiated by ethyl dimethylaminopropyl carbodiimide (Sigma-Aldrich) and
N-hydroxysuccinimide (Sigma-Aldrich) and then converted to maleimide (MAL) groups by
N-(2-aminoethyl) maleimide (Sigma-Aldrich). The MAL-modified fibers were cryogenically
milled, sterilized with 70% ethanol. All three components of NHC were stored individually
at −20 ◦ C, and thawed 30 min prior to use. NHC was prepared by mixing MAL-modified
fibers (10 mg/mL) into a mix of HA-SH (4 mg/mL; ESI BIO, Alameda, CA) and PEGDA
(2 mg/mL; ESI BIO) in sterile phosphate-buffered saline (PBS) [22,25] on ice. We mixed
and injected NHC or MSC-NHC within 15 min after exposing the contused spinal cord (see
below Section 2.4). Once mixed, NHC can be kept on ice for 6 h for injections.
2.3. MSC Preparation
MSCs were harvested from bone marrow from femurs and tibias of adult female
Sprague Dawley rats (n = 6) following a previously described protocol [9,26]. MSCs were
cultured on poly-D-lysine-coated dishes in Dulbecco’s Modified Eagle Medium (DMEM;
Sigma-Aldrich) with 10% fetal bovine serum (Mediatech; Herndon, VA, USA), 0.03% Lglutamine (Sigma-Aldrich), and 0.1% gentamycin (VWR; Radnor, PA, USA). The cells
were transduced with lentiviral vectors encoding for green fluorescent protein (GFP) at a
multiplicity of infection of 100, passaged 4 times, and then harvested for transplantation [9].
MSC remained on ice until mixing with freshly prepared NHC or sterile PBS prior to
injection into the epicenter of the spinal cord contusion.
2.4. Spinal Cord Contusion and Injection
Rats were anesthetized using an intraperitoneal injection of ketamine (50 mg/kg;
Zoetis; Parsippany, NJ, USA) and dexmedetomidine (0.5 mg/kg; Zoetis). In the absence of
corneal, hindlimb, and tail pinch reflexes, the rats were shaved and cleaned with Nolvasan®
skin and wound cleaner (Zoetis). Refresh® Lacri-Lube® eye ointment (Allergan; Madison,
NJ, USA) was applied to the eyes to prevent drying during surgery. The 9th thoracic spinal
cord segment was exposed and impacted onto its dorsal midline with a force of 175 kDyne
using the Infinite Horizon IH-0400 impactor (Precision Systems and Instrumentation LLC;
Versailles, KY, USA) [27] resulting in a bilateral injury, as previously described [9,10,28].
After rinsing the injury site with sterile lactated Ringers’ solution containing 0.1% gentamicin (VWR), the muscles were sutured, and the skin closed with Michel wound clips (Fine
Science Tools; Foster City, CA, USA). The rats received a subcutaneous injection of the α2adrenergic receptor antagonist, atipamezole (antisedan; 1.5 mg/kg; Zoetis) to reverse the
sedative and analgesic effects of dexmedetomidine. Laboratory personnel monitored the
rats until fully awake and applied after-surgery treatments as previously described [9,10].
At 3 days after injury, rats were anesthetized using an intraperitoneal injection of
ketamine (50 mg/kg; Zoetis) and dexmedetomidine (0.5 mg/kg; Zoetis). The contused
spinal cord was exposed and the injury epicenter was injected with a total volume of
5 µL with 500,000 MSC in NHC or PBS, or with NHC or PBS only at a rate of 1 µL/min
using a 10 µL Hamilton syringe, fitted with a pulled glass needle, fixed to a stereotaxic
device [6,9]. The internal diameter of the pulled glass needles was, on average, 120 µm; no
clogging of the needle was observed during the injections. The needle was kept in place
for 5 min after the injection was completed to prevent backflow. Possible leakage was
verified using a UV flashlight to detect green fluorescence on the spinal cord. Note that for
NHC, the individual components were mixed and injected within 15 min after exposing
the contused spinal cord. For MSC-NHC, the NHC was mixed first and then the MSC was
mixed into the NHC and injected within 15 min after exposing the contusion site. After the
injection was completed, the muscles were sutured, and the skin was closed with Michel
wound clips (Fine Science Tools). The rats received an intraperitoneal injection of antisedan
(1.5 mg/kg; Zoetis) to reverse the anesthesia. Laboratory personnel monitored the rats
until fully awake and applied after-surgery treatments as previously described [9,10]. Each
of the four experimental groups contained 15 rats, which survived for 1 week (n = 5) or
8 weeks (n = 10) after injury. The rats that survived for 1 week were fixed (see histological
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preparations) and their spinal cord was used for histological and anatomical assessments.
The rats that survived for 8 weeks were used to evaluate hind limb motor function during
survival (n = 10) and, after fixation (see histological preparations), for histological and
anatomical assessments (n = 5; randomly selected). Two rats died during surgery and
were replaced.
2.5. Assessment of Hind Limb Function
Hind limb overground walking was assessed weekly using the Basso, Bresnahan, Beattie (BBB) open-field walking test [9,29]. Individual values were averaged per experimental
group per time point. In addition, we assessed hind limb sensorimotor function at 4 and
8 weeks after injury using the horizontal ladder test [9,30,31]. For this, personnel blinded
to the treatment used high-definition video recordings of the ladder crossings to enable
accurate quantification of foot and leg slips, which were qualified as medium or large slips,
respectively. The total sum of medium and large slips was expressed as a percentage of
the number of steps taken to cross the ladder and averaged per rat and per group for each
time point.
2.6. Histological Preparations
At 1 and 8 weeks after injury, rats were deeply anesthetized and transcardially perfused
with 300 mL of PBS followed by 400 mL of 4% paraformaldehyde in PBS [9]. We dissected
the spinal cord from the rats and kept them in the same fixative overnight, followed by
30% sucrose in PBS for 2 days. We then removed a 12 mm long segment centered on the
contusion of each spinal cord and embedded these in frozen section medium (NEG 50;
Richard-Allan Scientific, Thermo Fisher Scientific, Kalamazoo, MI, USA). The embedded
frozen segments were cut into twelve series of 20 µm thick horizontal sections on a cryostat
(CM 1950; Leica Biosystems; Buffalo Grove, IL, USA). Each series represented the width
of the spinal cord with sections at 240 µm intervals. The sections were collected on glass
slides and stored at −20 ◦ C until staining.
2.7. Immunohistochemistry
For immunostaining, 20 µm thick tissue sections were rinsed for 5 min in PBS and
incubated in PBS with 5% normal goat serum and 0.3% Triton X-100 for 1 h at room
temperature to block non-specific antibody binding and permeabilize the tissue. Next, the
sections were incubated with primary antibodies (Table 1) mixed in PBS with 5% normal
goat serum and 0.3% Triton X-100 for 2 h at room temperature, followed by overnight at
4 ◦ C. Subsequently, the sections were rinsed 3 times for 5 min in PBS and then incubated
with goat secondary antibodies (Alexa Fluor 488, Alexa Fluor 555, or Alexa Fluor 647; 1:500;
Invitrogen; Carlsbad, CA, USA) against the host of the primary antibody, mixed in PBS, for
2 h at room temperature. After this incubation, the sections were rinsed 3 times for 5 min
in PBS, counterstained for 3 min with the nuclear marker, 40 ,6-diamidino-2-phenylindole
(DAPI; ThermoFisher Scientific; Waltham, MA, USA), rinsed 2 times for 5 min in PBS, and
then covered with a glass slip with fluorescence mounting medium (DAKO; Agilent; Santa
Clara, CA, USA). The 3 middle sections of the contusion site in a series were identified
and imaged using the Olympus VS120 slide scanner with 10× (UPISAPO, 0.4NA, Air) or
20× (UPISAPO, 0.75NA, Air) objectives and fitted with a Hamamatsu ORCA-Flash 4.0
camera (Hamamatsu; Bridgewater, NJ, USA). Autofocus was set on the DAPI channel for
cell quantification, and on the axon marker channel for axon quantification.
2.8. Injury Volume Assessment
For measuring the injury volume, we used the ImageJ measure function on sections
stained for glial fibrillary acidic protein (GFAP) at 1 and 8 weeks after injury. The injury site
was defined by the inner border of the surrounding GFAP+ scar. The injury site volume was
determined by taking the surface area of the injury site in the middle section, multiplied by
the known distance between sections, and adding up the surface area of the edge sections
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multiplied by 1/2 of the known distance between sections [22]. The individual injury
volumes were averaged per experimental groups.
Table 1. Source, catalog number, and dilution of the used primary antibodies.
Primary Antibody *

Source

Catalog Number

Dilution **

Rabbit anti-GFP

Millipore

AB3080P

1:1000

Mouse anti-GFAP

Sigma

G3893

1:500

Rabbit anti-GFAP

PhosphoSolutions

620-GFAP

1:1000

Mouse anti-ED1 (CD68)

Millipore

MAB1435

1:200

Rabbit anti-NeuN

Millipore

ABN78

1:500

Rabbit anti-CD206

Abcam

Ab64693

1:500

Rabbit anti-CD86

Abcam

Ab53004

1:500

Rabbit anti-NFh

Millipore

AB1991

1:500

* All antibodies are commercially available. Their source and catalog number are listed. ** Dilutions in PBS with
5% normal goat serum and 0.3% Triton X-100.

2.9. Automated Quantification
An ImageJ Find Maxima plugin (modified from [32]) was used for the automated
quantification of cells and axons. Images were corrected for the background by subtracting
a Gaussian filtered image, converted to 8-bit, and thresholded to create a count mask. For
CD86+ or CD206+ macrophages, two thresholded images from the general macrophage
marker, CD68, and from each of the polarization markers were used to create double count
masks, each overlaying the thresholded DAPI filter image. For GFP+ MSC, a thresholded
image from GFP was used to create a count mask to overlay the thresholded DAPI filter
image. Particles that were positive for both the count mask and DAPI were summed to
determine the total count of positive hits. The average particle size of ten randomly selected
nuclei for the specific cell of interest was used to create a multiplication factor to account
for multiple overlaying nuclei. Total counts were multiplied by the multiplication factor to
acquire standardized counts, which were averaged per rat and per experimental group.
2.10. Macrophage Quantification
We used automated quantification to evaluate CD68+, CD86+, and CD206+ macrophages
in the spinal cord at 1 and 8 weeks after injury. Quantification was performed in each of the
middle three sections of the contusion, in a 1.5 × 2 mm region of interest centered on the
midpoint of the injury. This selected 2 mm long and 1.5 mm wide region of interest covered
the injury site for 1 mm caudal and rostral from the midpoint of the contusion. CD68 is a
pan-macrophage marker, CD86 is a pro-inflammatory macrophage marker, and CD206 is an
anti-inflammatory macrophage marker. While recognizing the range of phenotypes among
macrophages within an injury site, we used CD86 to indicate a pro-inflammatory (M1-like)
macrophage phenotype and CD206 to indicate an anti-inflammatory (M2-like) macrophage
phenotype. We determined cell segmentation counts (DAPl+) residing within doublepositive (CD86+/CD68+ and CD206+/CD68+) masks. We standardized the counts by
dividing the average particle size by the average size of 10 nuclei of each of the macrophage
populations to create a multiplication factor to account for multiple overlaying nuclei. We
reported our particle counts multiplied by the multiplication factor as the standardized
average count, which were averaged per rat and then per group. We determined the total
number of macrophages and the CD206/CD86 ratio. Counts were averaged per rat and
per experimental group.
2.11. Astrocyte Presence Examination
Automated quantification was used to evaluate GFAP+ astrocytes in the injured spinal
cord at 1 and 8 weeks after injury. Quantification was performed in each of the middle
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three sections of the contusion, in a 2.5 × 4 mm region of interest centered on the midpoint
of the injury. This selected 4 mm long and 2.5 mm wide region of interest covered the
injury site and adjacent glia scar for 2 mm caudal and rostral from the midpoint of the
contusion. The total area and the percent area of GFAP were determined using the batch
threshold and measure function of ImageJ. Measurements were averaged per rat and per
experimental group.
2.12. Axon Presence
We used automated quantification to evaluate axons, recognized with antibodies
against neurofilament high molecular weight (NFh), in the contusion at 8 weeks after injury.
Quantification was performed in each of the middle three sections of the contusion, in a
1.5 × 2 mm region of interest centered on the midpoint of the injury. This selected 2 mm
long and 1.5 mm wide region of interest covered the injury site for 1 mm caudal and rostral
from the midpoint of the contusion. The total area and the percent area positive for NFh
were determined at 8 weeks after injury. Standardized ImageJ algorithms were used for
batch thresholding of all images, and all measurements were averaged per rat and per
experimental group.
2.13. Transplant Survival Assessment
Automated quantification was used to quantify GFP+ MSC in the contusion at 1 and
8 weeks after injury. Quantification was performed in each of the middle three sections
of the contusion, in a 2 × 2 mm region of interest centered on the midpoint of the injury.
This selected 2 mm long and 2 mm wide region of interest covered the injury site for
1 mm caudal and rostral from the midpoint of the contusion. Positive particles for the
GFP count mask and DAPI were quantified to determine the total number of positive hits.
We standardized the counts by dividing the average particle size by the average size of
10 nuclei of GFP+ MSC to create a multiplication factor to account for multiple overlaying
nuclei. We reported our particle counts multiplied by the multiplication factor as the
standardized average count, which were averaged per rat and per experimental group.
2.14. Statistical Analyses
Data were shown as means ± SEM (standard error of the mean). For statistical
analyses, we used IBM SPSS Statistics for Windows, version 24 (IBM; Armonk, NY, USA).
Data were analyzed by nonparametric ANOVA (independent-samples Kruskal–Wallis test)
or parametric (or nonparametric) repeated-measures ANOVA (Friedman’s test), followed
by Bonferroni post hoc correction, unless otherwise stated. Pearson’s correlation analysis
was used to determine the relationship between variables expressed by the coefficient
of determination (r2 ) and considered strong when r2 > 0.5. Differences were accepted as
statistically significant if p < 0.05.
3. Results
3.1. Inflammatory Response in the Injury Site
We assessed the number of macrophages in the injury site at 1 and 8 weeks after injury.
Macrophages were present in the injury site at both time points, irrespective of the treatment. Figure 1 shows CD68+ macrophages in the injury site with MSC-NHC (Figure 1A),
MSC-PBS (Figure 1B), NHC (Figure 1C), or PBS (Figure 1D) at 1 week after injury. The
areas outlined in Figure 1A–D are enlarged in Figure 1A’–D’, respectively. We found
458 ± 75 (mean ± SEM) macrophages in the injury site with MSC-NHC, 1997 ± 174 with
MSC-PBS, 565 ± 94 with NHC, and 1699 ± 151 with PBS (Figure 1E). The 4.4-fold decrease
in total macrophage count with MSC-NHC compared with MSC-PBS (p < 0.05) and the
3.7-fold decrease in macrophages between MSC-NHC and PBS (p < 0.05) were significantly
different. The 3-fold decrease in macrophages with NHC compared with PBS (p < 0.05)
and the 3-fold decrease with NHC compared with MSC-PBS (p < 0.05) were significantly
different. At 8 weeks after injury, there were 833 ± 128 (average ± SEM) macrophages
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To assess the relative amount of CD206+ anti-inflammatory, pro-regenerative (M2-like)
macrophages vs. CD86+ pro-inflammatory (M1-like) macrophages, we quantified the
CD206+/CD86+ ratios at 1 and 8 weeks after injury by analyzing tissue sections stained
with antibodies against CD206/CD68 and CD86/CD68. CD206 and CD86 are markers for M2-like and M1-like macrophages, respectively. Figure 2 shows CD206+/CD68+
macrophages in the injury site with MSC-NHC (Figure 2A), MSC-PBS (Figure 2B), NHC
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(Figure 2C), or PBS (Figure 2D) at 8 weeks after injury. The areas outlined in Figure 2A–D
are enlarged in Figure 2A’–D’ and show CD206+/CD68+ macrophages, and Figure 2A”–D”
shows the same macrophages stained only for CD68. Moreso, shown are the CD86+/CD68+
macrophages in the injury site with MSC-NHC (Figure 2E), MSC-PBS (Figure 2F), NHC
(Figure 2G), or PBS (Figure 2H) at 8 weeks after injury. The areas outlined in Figure 2A–D
are enlarged in Figure 2A’–D’ and show CD206+/CD68+ macrophages, and Figure 2A”–D”
shows the same macrophages stained only for CD68. At 1 week after injury, we found that
the CD206+/CD86+ ratio was 1.72 ± 0.35 in the injury site with MSC-NHC, 0.57 ± 0.09 with
MSC-PBS, 1.29 ± 0.33 with NHC, and 0.24 ± 0.11 with PBS (Figure 2I). The CD206+/CD86+
ratio was significantly higher (p < 0.05) with MSC-NHC than with MSC-PBS and with PBS.
The CD206+/CD86+ ratio was significantly higher with NHC than with PBS (p < 0.05).
At 8 weeks after injury, the CD206+/CD86+ ratio was 4.96 ± 1.32 in the injury site with
MSC-MHC, 1.41 ± 0.97 with MSC-PBS, 3.34 ± 0.81 with NHC, and 0.79 ± 0.38 with PBS
(Figure 2J). At this time point, the CD206+/CD86+ ratio was significantly higher (p < 0.05)
with MSC-NHC than with MSC-PBS or PBS (p < 0.05). The results showed that treatment
Cells 2022, 11, x FOR PEER REVIEW
9 of 18
with MSC-NHC compared with MSC-PBS facilitated the polarization of macrophages in
the injury site towards the pro-regenerative phenotype.

Figure 2. Inflammation polarization ratios in the injury site. Photomicrographs showing macrophages
Figure
polarization
ratios in the
injury site.marker,
Photomicrographs
macrostained2.
forInflammation
CD206 (white),
an anti-inflammatory
macrophage
CD68 (red), a showing
pan-macrophage
phages
stained
for
CD206
(white),
an
anti-inflammatory
macrophage
marker,
CD68
(red),
panmarker, and the nucleus marker, DAPI (blue), in the injury site with MSC-NHC (A), MSC-PBS (B)a NHC
macrophage marker, and the nucleus marker, DAPI (blue), in the injury site with MSC-NHC (A),
MSC-PBS (B) NHC (C), or PBS (D) at 8 weeks after injury. Images in panels (A’–D’) (showing CD206,
CD68, and DAPI) and (A’’–D’’) (showing CD68 and DAPI) are enlargements of the outlined area in
panels (A–D), respectively. Scale bar in (A,C) is 250 µm, and 200 µm in (B,D). The scale bar in
(A’/A’’) and (D’/D’’) is 15 µm, and 25 µm in (B’/B’’) and (C’/C’’). In (A–D), the rostral (R) and caudal
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(C), or PBS (D) at 8 weeks after injury. Images in panels (A’–D’) (showing CD206, CD68, and DAPI)
and (A”–D”) (showing CD68 and DAPI) are enlargements of the outlined area in panels (A–D),
respectively. Scale bar in (A,C) is 250 µm, and 200 µm in (B,D). The scale bar in (A’/A”) and (D’/D”)
is 15 µm, and 25 µm in (B’/B”) and (C’/C”). In (A–D), the rostral (R) and caudal (C) orientation of
the horizontal sections are indicated. Photomicrographs showing macrophages stained for CD86
(white), a pro-inflammatory macrophage marker, CD68 (red), a pan-macrophage marker, and the
nucleus marker, DAPI (blue), in the injury with MSC-NHC (E), MSC-PBS (F) NHC (G), or PBS (H) at
8 weeks after injury. The scale bar in (E–H) is 250 µm. (I) Bar graph of the M2/M1 macrophage ratio
in the injury site of each group at 1 week after injury. The M2/M1 ratio was significantly higher with
MSC-NHC and NHC only than with MSC-PBS and PBS only. There was no statistically significant
difference in the M2/M1 ratio of MSC-PBS and NHC only. (J) Bar graph of the M2/M1 macrophage
ratio in the injury site of each group at 8 weeks after injury. The M2/M1 ratio was significantly
higher with MSC-NHC and NHC only than with MSC-PBS and PBS only. There was no statistically
significant difference in the M2/M1 ratio of MSC-PBS and NHC only. In both graphs, the asterisks
indicate p < 0.05, and the bars represent SEM. Abbreviations: DAPI = 40 ,6-diamidino-2-phenylindole;
MSC = mesenchymal stromal cells; NHC = nanofiber-hydrogel composite; PBS = phosphate-buffered
saline; SEM = standard error of the mean.

3.2. Injury Site Volume
We measured the average volume of the injury site at 1 and 8 weeks after injury. In all
animals, an injury site surrounded by a GFAP+ astrocyte scar was discernable at both times
after injury. Figure 3 shows the injury site in rats treated with MSC-NHC (Figure 3A), MSCPBS (Figure 3B), NHC (Figure 3C), or PBS (Figure 3D) at 8 weeks after injury. The volume of
the injury site at 1 week after injury was 2.48 ± 0.40 mm3 (average ± SEM) with MSC-NHC,
2.72 ± 0.34 mm3 with MSC-PBS, 2.88 ± 0.24 mm3 with NHC, and 2.44 ± 0.31 mm3 with
PBS (Figure 3E). There were no statistical differences among these volumes. At 8 weeks after
injury, the volume of the injury site was 1.77 ± 0.28 mm3 (average ± SEM) with MSC-NHC,
2.58 ± 0.35 mm3 with MSC-PBS, 1.91 ± 0.28 mm3 with NHC, and 3.95 ± 0.30 mm3 with
PBS (Figure 3F). Thus, we found a 31 % decrease in injury size with MSC-NHC compared
with MSC-PBS (p < 0.05), a 55 % decrease in injury size with MSC-NHC compared with PBS
(p < 0.05), and a 51 % decrease in injury size with NHC compared with PBS (p < 0.05). These
results showed that MSC-NHC delivery did not result in a significant change in lesion size
at 1 week after injury (i.e., 4 days after treatment) over MSC-PBS, NHC, or PBS; however,
MSC-NHC and NHC only both limited the secondary injury and yielded a significantly
smaller injury compared with MSC-PBS and PBS at week 8.
3.3. Astrocytes in the Injury Site
The presence of GFAP+ astrocytes in the injury site was evaluated at 1 and 8 weeks
after injury. Figure 3 shows the GFAP-surrounded injury site in rats treated with MSC-NHC
(Figure 3A), MSC-PBS (Figure 3B), NHC (Figure 3C), or PBS (Figure 3D) at 8 weeks after
injury. At 1 week after injury, GFAP staining occupied 3.43 ± 0.66% (average ± SEM) of
the contused segment with MSC-NHC, 3.17 ± 0.73% with MSC-PBS, 4.21 ± 0.68% with
NHC, and 4.24 ± 0.75% with PBS (Figure 3G). There were no statistical differences among
these measurements. At 8 weeks after injury, GFAP staining occupied 10.46 ± 1.83%
(average ± SEM) of the contused segment with MSC-NHC, 5.08 ± 0.4 % with MSC-PBS,
8.59 ± 0.88% with NHC, and 5.36 ± 0.72% with PBS (Figure 3H). The 2.1-fold increase in
astrocytes within the injury site with MSC-NHC compared with MSC-PBS (p < 0.05) and
the 1.9-fold increase in astrocytes within the injury site with MSC-NHC compared with PBS
(p < 0.05) were statistically significant. The results indicated that treatment with MSC-NHC
compared with MSC-PBS resulted in a higher degree of astrocyte presence in the injury site.
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Figure 3. InjuryFigure
size volume
and
astrocyte
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size
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showing
astrocytes stained
for GFAP (red) for
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injury
site
with
MSC-NHC
(A),
MSC-PBS
(B),
NHC
(C),
or
PBS
(D)
at
8
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GFAP (red) in the injury site with MSC-NHC (A), MSC-PBS (B), NHC (C), or
PBS (D) at 8 weeks
after injury. The injury site was defined by the inner border of the GFAP+ scar. The scale bar in A is
after injury. The injury site was defined by the inner border of the GFAP+ scar. The scale bar in A is
600 µm, and 550 µm in (B–D). In (A–D), the rostral (R) and caudal (C) orientation of the horizontal
sections are indicated. (E) Bar graph showing the volume of the injury site at 1 week after injury.
There were no statistically significant differences between groups. (F) Bar graph showing the volume
of the injury site at 8 weeks after injury. The injury site was significantly smaller with MSC-NHC
compared with MSC-PBS or PBS only, with NHC compared with PBS, and with MSC-PBS compared
with PBS only. (G) Bar graph of the percentage area of the injury site positive for GFAP at 1 week
after injury. There were no statistically significant differences in astrocyte presence in the injury
site between the groups. (H) Bar graph of the percentage area of the injury site positive for GFAP
at 8 weeks after injury. There were significantly more astrocytes in the injury site with MSC-NHC
compared with MSC-PBS and PBS only. In all graphs, the asterisks indicate p < 0.05, and the bars
represent SEM. Abbreviations: GFAP = glial fibrillary acidic protein; MSC = mesenchymal stromal
cells; NHC = nanofiber-hydrogel composite; PBS = phosphate-buffered saline; SEM = standard error
of the mean.

3.4. Axons in the Injury Site
We quantified the presence of axons in the injury site at 8 weeks after injury. Figure 4
shows axons stained for NFh in the injury site treated with MSC-NHC (Figure 4A), MSC-
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PBS (Figure 4B), NHC (Figure 4C), or PBS (Figure 4D). The areas outlined in Figure 4A–D
are enlarged in Figure 4A’–D’, respectively. The NFh+ staining occupied 4.05 ± 0.29%
(average ± SEM) of the injury site area with MSC-NHC, 2.62 ± 0.28% with MSC-PBS,
3.07 ± 0.33% with NHC, and 1.28 ± 0.43% with PBS (Figure 4E). The 55% increase in
NFh+ axons within the injury site with MSC-NHC compared with MSC-PBS was statistically significant (p < 0.05). The 140% increase in NFh+ axons within the injury site with
NHC compared with PBS was statistically significant (p < 0.05). These results showed that
treatment with MSC-NHC compared with MSC-PBS resulted in an increased axon presCells 2022, 11, x FOR PEER REVIEW ence in the injury site. Pearson’s correlation analysis showed a strong positive association
12 of 18
2
between the axons and astrocytes (r = 0.56) in the injury site.
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3.5. MSC Transplant Survival
3.5. MSC Transplant Survival
We examined transplanted MSC survival in the injury site at 1 and 8 weeks after
We examined transplanted MSC survival in the injury site at 1 and 8 weeks after injury.
injury. GFP+ MSC were identified in the injury site at 1 week after injury (Figure 5A–D),
GFP+ MSC were identified in the injury site at 1 week after injury (Figure 5A–D), but
but not at 8 weeks after injury. At 1 week after injury, the relative MSC survival, in reference to the number of MSCs injected, was not significantly different between the group
with NHC (MSC-NHC; 41 ± 11%; average ± SEM) and the group without NHC (MSC-PBS;
29 ± 13%) (Figure 5E). Our data showed that mixing MSC into NHC compared with PBS
prior to injection into damaged nervous tissue in an adult rat contused spinal cord does

Cells 2022, 11, 1137

12 of 17

not at 8 weeks after injury. At 1 week after injury, the relative MSC survival, in reference
to the number of MSCs injected, was not significantly different between the group with
NHC (MSC-NHC; 41 ± 11%; average ± SEM) and the group without NHC (MSC-PBS;
Cells 2022, 11, x FOR PEER REVIEW 29 ± 13%) (Figure 5E). Our data showed that mixing MSC into NHC compared with
13PBS
of 18
prior to injection into damaged nervous tissue in an adult rat contused spinal cord does
not significantly affect their survival.

Figure 5. MSC transplant survival and hindlimb function. (A) Photomicrograph showing MSC
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3.6. Hindlimb Locomotor Function
3.6. Hindlimb Locomotor Function
We assessed hindlimb motor function using an open-field (BBB) test [29] and hind limb
We assessed
hindlimb
function
using
open-field
test as
[29]
and hind
sensorimotor
function
using amotor
horizontal
ladder
test an
[30].
Hindlimb(BBB)
function,
determined
limb
sensorimotor
function
using
a
horizontal
ladder
test
[30].
Hindlimb
function,
as deby the BBB score, was similar across the groups after injury and after the subsequent
termined
by
the
BBB
score,
was
similar
across
the
groups
after
injury
and
after
the
subsetreatment. The average BBB score per experimental group at 1 day after injury was 0.1 ± 0.1
quent treatment.
average
score per0.0
experimental
group at 1 1.5
day±after
injury
was
(average
± SEM) The
for rats
withBBB
MSC-NHC,
± 0.0 with MSC-PBS,
0.5 with
NHC,
0.1
±
0.1
(average
±
SEM)
for
rats
with
MSC-NHC,
0.0
±
0.0
with
MSC-PBS,
1.5
±
0.5
with
and 1.0 ± 0.5 with PBS (Figure 5F). The average BBB scores gradually increased to reach
NHC,
1.0rats
± 0.5
with
PBS (Figure
5F).
average
BBB scores
to
10.8
± and
0.1 in
with
MSC-NHC,
10.9
± The
0.1 with
MSC-PBS,
11.0 gradually
± 0.1 withincreased
NHC, and
reach 10.8 ± 0.1 in rats with MSC-NHC, 10.9 ± 0.1 with MSC-PBS, 11.0 ± 0.1 with NHC,
and 10.6 ± 0.2 with PBS (Figure 5F) at 4 weeks after injury. These scores were maintained
for the following weeks until the 8-week endpoint. Hindlimb sensorimotor function as
assessed on the horizontal ladder was similar among all experimental groups at 4 and 8
weeks after injury (Figure 5G).
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10.6 ± 0.2 with PBS (Figure 5F) at 4 weeks after injury. These scores were maintained for the
following weeks until the 8-week endpoint. Hindlimb sensorimotor function as assessed
on the horizontal ladder was similar among all experimental groups at 4 and 8 weeks after
injury (Figure 5G).
4. Discussion
The repair potential of MSC-NHC was evaluated in a model of spinal cord contusion.
A contusion is the prevalent mechanism of SCI in the clinic. We found that the early inflammatory response in the contused spinal cord of adult rats was substantially attenuated
by treatment with MSC-NHC or NHC only, but not with MSC-PBS. Macrophages are
necessary in the damaged spinal cord nervous tissue for clearance of cellular/tissue debris
and the restoration of homeostasis [33]. During the process, macrophages secrete cytotoxic
molecules that may contribute to the propagation of nervous tissue damage in the spinal
cord [34,35]. Attenuation of the number of macrophages early after SCI is considered to
support nervous tissue repair [36], and this notion was substantiated in previous studies
(e.g., [33,34]). The observation that treatment with NHC resulted in a reduction in the
macrophage number in the contusion site was consistent with previous findings [22]. We
anticipated that treatment with MSC-PBS would not cause a decrease in the number of
macrophages in the injury site. While studies have reported anti-inflammatory effects of an
MSC transplant [15–18], this particular MSC-mediated effect has not been associated so far
with fewer total macrophages in the injured spinal cord.
The absence of a reduction in the macrophage number in the contusion site with MSCPBS treatment combined with the decrease in the macrophage number with MSC-NHC
and NHC only treatment, points at NHC as the chief mediator of the observed decline in
macrophages elicited by MSC-NHC treatment. This proposition would also explain the
similar reduction in macrophage numbers by MSC-NHC and NHC only. The ability of
NHC to lower the presence of macrophages in an injury site in the spinal cord supports its
use as a matrix for cell transplants. Moreover, this finding warrants further investigation of
possible mechanisms that underlie the anti-inflammatory effects of NHC.
The inflammatory response in the contused spinal cord of adult rats shifted from
a pro-inflammatory-dominant response (low CD206+/CD86+ ratio) towards an antiinflammatory, pro-regenerative-dominant response (high CD206+/CD86+ ratio) by treatment with MSC-NHC or NHC only, but not with MSC-PBS. A shift in macrophage polarization in the injury site changes their secretome, and thus the molecular environment,
in support of tissue remodeling and repair [34,36]. In the injured spinal cord, the chronic
pro-inflammatory environment is considered a key contributing factor to continuing nervous tissue damage [33,36]. Our earlier published report on NHC effects on spinal cord
repair following SCI supports the finding that NHC modulated macrophages towards a
pro-regenerative phenotype [22]. The mechanisms of NHC-mediated macrophage modulation are unknown, but the specific structural design of NHC, including its stiffness and the
presence of electrospun fibers, has been proposed to be involved in its immunomodulatory
effects [22]. The absent immunomodulatory effect in the contusion site with MSC-PBS
treatment was unexpected because previous studies reported that a transplant of MSC
exerts such an effect among macrophages present in damaged nervous tissue [7,15–17]. It
has been suggested that transplanted MSC mediate a change in macrophages towards a proregenerative phenotype through paracrine signaling by molecules, such as indoleamine [37]
and interleukin-10 [38]. The absence of this effect in our study may be related to factors,
such as the severity of the injury or the dose of MSC. In addition, because of the dynamic
nature of the inflammatory response, the time of treatment may also play a role in the
degree of MSC-mediated modulation of the immune response in the injury site.
The macrophage polarizing effect was greater with MSC-NHC than with MSC-PBS. It
is possible that MSC within NHC is less susceptible to injury-derived factors that would
decrease their production of molecules directing a macrophage phenotype shift, or alternatively, are more susceptible to factors that would support the secretion of molecules that
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promote a macrophage phenotype shift. Another possibility is that immunomodulation
of the macrophages is promoted by mechanical/physical cues from the NHC besides the
soluble factors [39,40]. We can rule out the possibility that MSC survival was improved—
which could also result in more molecules that lead to macrophage polarization—because
we found similar degrees of survival of MSC in NHC or PBS. The observed interaction
between MSC and NHC to trigger the crucial macrophage phenotype shift is a compelling
advantage for their combined use for SCI treatment. The critical role of inflammation in
SCI [33,41] warrants a future study of mechanisms underlying NHC-mediated modulation
of the inflammatory response.
Secondary loss of nervous tissue in the contused spinal cord segment was limited
by treatment with MSC-NHC, NHC only, and MSC-PBS. Loss of nervous tissue after the
primary damage is a hallmark of SCI. Mechanistically, the primary insult triggers a series
of molecular and cellular cytotoxic events that, in concert, cause further nervous tissue
damage and degeneration [1,2]. Protecting nervous tissue from secondary damage is an
important early line of defense to limit the devastating consequences of SCI [42]. We found
that MSC and NHC both have neuroprotective effects that limit injury expansion in the
spinal cord. An MSC transplant may exert neuroprotective effects through the secretion
of neuroprotective molecules, including neurotrophins (e.g., [12,13,43]. The finding that
NHC has neuroprotective effects is in agreement with earlier published observations [22].
The mechanisms of NHC-mediated neuroprotection are under investigation. It is possible
that the anti-inflammatory effects of NHC indirectly contribute to its neuroprotective
effects [9,34,44].
Neuroprotection in the contused spinal cord by NHC alone and MSC-PBS treatment
was similar, while neuroprotection by MSC-NHC treatment was significantly stronger
than by MSC-PBS treatment. It is possible that the presence of NHC provided a more
favorable environment for the MSC to secrete neuroprotective molecules. There was no
significant difference in MSC survival in NHC or PBS, which rules out the possibility
that neuroprotective molecules were secreted for a prolonged time due to an extended
MSC presence. The significance of neuroprotection in SCI is a compelling argument to
use NHC as a transplant matrix for MSC. Future studies will need to focus on elucidating
mechanisms underlying the MSC-NHC interactions that support nervous tissue repair.
The presence of axons and astrocytes in the injury site was increased with MSCNHC. Providing an environment in the injury site that supports the presence of astrocytes
and axons is important for the overall repair after spinal cord damage because they may
contribute to re-establishing neural tissue and neural connections. Astrocytes and axons are
often found closely associated with an injury site in the spinal cord [22]; such a relationship
was also observed in the present study. Interestingly, our data suggest that the combined use
of MSC and NHC facilitated the establishment of an environment beneficial for astrocytes
and axons. Several studies demonstrated that a transplant of MSC supports axon presence
in an injury site in the spinal cord [19,20]. The presence of NHC in a spinal cord contusion
was shown to result in an increased axon presence [22]. We now show that the MSC and
NHC combination resulted in more axons and astrocytes in the injury site compared with
either of the single treatments.
Our results showed that an MSC-NHC transplant resulted in an attenuated immune
response, macrophage polarization, reduced injury size, and increased axons and astrocytes
in the injury site compared with MSC-PBS. These changes did not translate into improved
hindlimb function recovery in the used model of contusive SCI, as was shown using the
BBB scale and the horizontal ladder walking test. The combinatorial MSC-NHC treatment
was investigated for its hypothesized ability to elicit nervous tissue repair in the contused
spinal cord. Improved morphological outcomes do not necessarily guarantee improvements in functional outcomes. In this study, the benefit of the observed improvements in
morphological outcomes may lie in an increased likelihood and/or efficacy of additional
interventions that aim to recover function.
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We found that the volume of the injury site was significantly smaller in rats with
MSC-PBS compared with PBS, which is in agreement with previous reports [5,6,8,9]. On
the other hand, we did not find significant differences in macrophage number, macrophage
polarization towards a pro-regenerative phenotype, and astrocyte and axon presence in
the injury site between rats with MSC-PBS compared with PBS, which is in discord with
prior publications [7,18–20]. The absence of these latter repair-supporting effects in rats
with MSC-PBS relative to rats with PBS only could be due to the use of MSC derived from
bone marrow, which, relative to, for instance, adipose-derived MSC, are characterized by
lower in vivo survival and less axon protection in the injured spinal cord [45,46]. Another
possibility is that the number of MSC transplanted into the injury may have been too small,
compared with previous studies [6,9]. Moreso, the day of transplantation may have affected
the outcomes. We injected MSC three days after injury, which is when the inflammatory
response reaches its peak [33,34,36].
Our results show that MSC-NHC treatment elicits greater immunomodulation and
neuroprotection compared to MSC-PBS or NHC alone. It is possible that the larger effect of
MSC-NHC on nervous tissue protection is, at least in part, due to the stronger modulation of
the immune response towards a pro-regenerative phenotype. Importantly, our data showed
the strongest shift in the immune response and largest neuroprotection with MSC-NHC
than with MSC-PBS. These effects were not the result of improved survival of MSC within
the NHC matrix. Future studies will need to investigate mechanisms of the relationship
between MSC and NHC and explore if other types of repair-mediating cells would also
benefit from NHC as their transplant matrix. The observed interactions between MSC and
NHC provide an exciting advantage for their combined use for SCI treatment.
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